Shares of Homology Medicines (NASDAQ:FIXX) have been given a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 12 month consensus price objective of $30.67 for the company and are predicting that the company will post ($4.25) EPS for the current quarter, according to Zacks. Zacks has also assigned Homology Medicines an industry rank of 231 out of 265 based on the ratings given to related companies.

FIXX has been the subject of a number of recent analyst reports. Bank of America initiated coverage on Homology Medicines in a report on Monday, April 23rd. They set a “buy” rating and a $27.00 target price for the company. Evercore ISI initiated coverage on Homology Medicines in a report on Monday, April 23rd. They set an “outperform” rating and a $30.00 target price for the company. Cowen initiated coverage on Homology Medicines in a report on Monday, April 23rd. They set an “outperform” rating for the company. Finally, BTIG Research initiated coverage on Homology Medicines in a report on Tuesday. They set a “buy” rating and a $35.00 target price for the company.

NASDAQ:FIXX opened at $20.85 on Wednesday. Homology Medicines has a fifty-two week low of $16.12 and a fifty-two week high of $24.40.

In other news, insider James E. Flynn acquired 1,250,000 shares of the firm’s stock in a transaction on Monday, April 2nd. The stock was acquired at an average price of $16.00 per share, for a total transaction of $20,000,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Vida Ventures, Llc acquired 375,000 shares of the firm’s stock in a transaction on Monday, April 2nd. The stock was purchased at an average price of $16.00 per share, with a total value of $6,000,000.00. The disclosure for this purchase can be found here.

Homology Medicines Company Profile

There is no company description available for Homology Medicines Inc

Get a free copy of the Zacks research report on Homology Medicines (FIXX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.